Figure 5.
Survival analysis graph with the outcome of “drug discontinuation due to relapses, disability progression, and adverse events” (a) among all patients in the rituximab cohort and (b) among RRMS patients.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.